Recognising coexisting disease and choosing treatment when both conditions are present.

Asthma and chronic obstructive pulmonary disease can coexist in the same patient. Identifying both conditions matters because it affects the choice of inhaled treatment, the interpretation of investigations and the risk of future exacerbations.

GOLD 2027 emphasises that when asthma accompanies COPD, treatment should primarily follow asthma guidance and include an inhaled corticosteroid (ICS). Bronchodilation remains important for persistent symptoms and airflow limitation.

The report also introduces a shared GOLD–GINA vision addressing access to diagnosis, affordable inhalers, specialist care and pulmonary rehabilitation. This adds a broader health-system perspective to the clinical task of managing patients with features of both diseases. GOLD 2027 report, pages 2, 68 and 135–136

What is new in GOLD 2027?

The new section, “Addressing the Global Challenges of COPD and Asthma — A Shared Vision from GOLD & GINA,” incorporates the organisations’ joint statement published in 2026.

Its accompanying figure highlights several barriers shared by patients with asthma and COPD.

AreaShared challenge
Diagnostic testingLimited availability of spirometry and peak-flow meters
Primary careDifficulties accessing tests and interpreting results
Inhaled treatmentAvailability and affordability of inhalers
Specialist careAccess to appropriate facilities
RehabilitationAvailability of pulmonary rehabilitation programmes
Financial burdenPatient expenses and health-system costs
PreventionTobacco exposure and other harmful inhaled exposures
Environmental healthClimate change and the carbon footprint of inhalers and exacerbations

The clinical advice on coexisting asthma and COPD appears elsewhere in the report, particularly in its pharmacological treatment and comorbidity chapters. Together, these sections connect appropriate treatment with the practical conditions needed to deliver it. GOLD 2027 report, Figure A and Chapters 3 and 5

Moving beyond the “overlap” label

GOLD has moved away from describing a separate asthma–COPD overlap syndrome. It recognises asthma and COPD as distinct, heterogeneous disorders that may coexist and share features such as eosinophilic inflammation or bronchodilator responsiveness.

GINA uses asthma+COPD as a descriptive term for people with features of both conditions. Such patients can have different histories, inflammatory patterns and structural abnormalities.

Documenting the evidence for each diagnosis helps guide treatment more precisely. A patient with established childhood asthma who later develops smoking-related emphysema may have different needs from a patient with longstanding asthma and persistent airflow limitation. GOLD 2027 report, page 68 , GINA strategy report, Chapter 7

When should coexisting asthma be considered?

In a patient labelled as having COPD, revisit the possibility of asthma when the history suggests variable airway disease or earlier respiratory symptoms.

GOLD highlights childhood asthma or bronchitis, a family history of asthma, wheezing, atopic manifestations, childhood respiratory infections and previous inhaled treatment as relevant clues.

FindingHow it contributes to assessment
Childhood or young-adult asthmaSupports a history of asthma, particularly when supported by records
Variable wheeze, breathlessness or chest tightnessPrompts assessment for variable airflow limitation
Atopy or family historyAdds support when consistent with the wider history
Smoking, biomass or occupational exposureSupports assessment for COPD alongside asthma
Persistent symptoms and obstructionRequires evaluation of chronic airway disease and alternative causes
Emphysema or gas trappingHelps characterise structural and physiological disease

Review the chronology carefully. Establish when symptoms began, whether they varied over time, which exposures preceded deterioration and what objective evidence supported previous diagnoses. GOLD 2027 report, pages 135–136

Establish the diagnosis with objective testing

Spirometry

Quality-assured spirometry is central to assessment. GOLD uses a post-bronchodilator FEV₁/FVC below 0.70 to identify persistent airflow obstruction in the appropriate clinical context.

Persistent obstruction can occur in longstanding asthma as well as COPD. Interpret the result alongside symptom variability, previous lung-function measurements, exposure history and imaging.

When a post-bronchodilator ratio lies between 0.60 and 0.80, GOLD advises confirmation on a separate occasion because biological variation can affect classification. In younger adults with persistent clinical suspicion despite a preserved fixed ratio, comparison with the lower limit of normal or z-score can help resolve uncertainty. GOLD 2027 report, pages 32–34

Bronchodilator responsiveness

GOLD states that bronchodilator responsiveness alone cannot reliably distinguish asthma, COPD or their coexistence. A response can occur in COPD, while asthma treated with ICS may show little variability at a particular visit.

Serial peak-flow measurements, repeat spirometry and historical evidence of variable airflow limitation may help when the diagnosis remains uncertain. Interpret these findings together. GOLD 2027 report, page 135 , GINA strategy report, Chapter 7

Eosinophils and FeNO

Blood eosinophils and fractional exhaled nitric oxide can support assessment of Type 2 inflammation. GOLD notes that values tend to be higher in patients with coexisting asthma and COPD, while emphasising their limited ability to distinguish the diagnoses.

Use biomarkers to inform the inflammatory assessment and relevant treatment decisions, alongside the clinical history. Eosinophilic COPD can occur in a patient who has no established asthma diagnosis. GOLD 2027 report, pages 135–136

CT and additional investigations

GOLD recommends careful review of lung CT in patients with suspected coexistence. Compared with COPD alone, these patients tend to have greater airway wall thickening, less emphysema and more mucus plugging.

Imaging also helps assess bronchiectasis, interstitial abnormalities, previous tuberculosis and other structural causes of symptoms. Additional lung-function testing or specialist investigations can be selected according to the diagnostic question. GOLD 2027 report, pages 135–136

Begin treatment with an ICS-containing regimen

The central treatment recommendation is clear. When asthma coexists with COPD, include ICS-containing therapy.

GOLD advises clinicians to primarily follow asthma pharmacotherapy guidance when concurrent asthma is suspected. It describes ICS use as mandatory when concomitant asthma is present.

GINA similarly prioritises asthma treatment while further investigations proceed in patients with features of both conditions. This protects against severe asthma exacerbations while the diagnosis and longer-term regimen are refined. GOLD 2027 report, page 68 , GINA strategy report, Chapter 7

Combine anti-inflammatory treatment with appropriate bronchodilation

Many patients require a long-acting beta₂-agonist (LABA), with a long-acting muscarinic antagonist (LAMA) added according to symptoms, exacerbations and response.

Treatment decisionPractical approach
Asthma is established alongside COPDInclude ICS and follow asthma treatment principles
Features of both conditions are present while investigations continueStart with ICS-containing treatment and reassess
Persistent symptoms despite ICS-containing treatmentReview technique, adherence, device suitability and other causes, then optimise bronchodilation
Ongoing symptoms or exacerbations despite ICS–LABAAssess suitability for additional LAMA and specialist review
Persistent exacerbations despite optimised inhaled therapyReassess the diagnosis and inflammatory profile before selecting further treatment

Long-acting bronchodilators without ICS are unsafe in patients with asthma because of the risk of severe exacerbations and death. GINA recommends an initial low or medium ICS dose for asthma+COPD, selected according to symptoms and adverse-effect risk, including pneumonia. Subsequent adjustments should follow response and the applicable asthma regimen. GINA strategy report, Chapter 7

Apply eosinophil thresholds to the relevant decision

In COPD, eosinophils help estimate the likely exacerbation-prevention benefit from ICS. GOLD uses different thresholds for considering initial triple therapy and for escalation during follow-up.

An established asthma diagnosis provides its own indication for ICS-containing treatment. Keep that indication explicit when reviewing the regimen, particularly if considering a reduction or withdrawal of ICS. GOLD 2027 report, Chapter 3

A practical clinical pathway

Chronic respiratory symptoms with possible persistent airflow limitation

↓

Review the history and perform quality-assured spirometry

Assess asthma history, variability, exposures, previous results and alternative diagnoses.

↓

Asthma is established or strongly suspected alongside COPD

Begin or maintain ICS-containing treatment while completing the assessment.

↓

Assess symptoms, exacerbations and treatment delivery

Check inhaler technique, adherence, device suitability, smoking and comorbidities.

↓

Optimise bronchodilation and non-pharmacological care

Add or adjust long-acting treatment according to the asthma regimen and clinical response. Address rehabilitation, vaccination and self-management.

↓

Persistent symptoms, exacerbations or uncertainty

Arrange specialist assessment and investigations directed at the unresolved problem.

This pathway summarises the clinical approach described across GOLD and GINA. GOLD 2027 report, Chapters 3 and 5 , GINA strategy report, Chapter 7

Include prevention, rehabilitation and self-management

At follow-up, ask whether the patient can obtain and use the prescribed treatment consistently. Observe inhaler technique and use teach-back to confirm understanding.

The care plan should include smoking cessation, reduction of harmful exposures, appropriate vaccination, physical activity and pulmonary rehabilitation when indicated. Provide an individual written action plan and explain how to recognise worsening symptoms and seek help.

Review comorbid conditions that can contribute to breathlessness or poor control, including cardiovascular disease, obesity, anxiety, depression, rhinitis and structural lung disease. GOLD 2027 report, Chapters 3 and 5 , GINA strategy report, Chapter 7

Reassess deterioration and exacerbations carefully

Patients with coexisting asthma and COPD have a greater burden of exacerbations and hospital use. During deterioration, assess severity and consider contributing conditions such as pneumonia, heart failure, arrhythmia and pulmonary embolism.

After an event, review what happened before escalating maintenance treatment. Check whether medication was available, doses were taken, inhalers were used correctly and the action plan was understood. Reassess the diagnosis if events are recurrent or atypical.

GOLD also emphasises cardiovascular risk during and after COPD exacerbations, making recovery an opportunity to review cardiac symptoms, risk factors and indicated treatment. GOLD 2027 report, Chapters 4 and 5

Refer when uncertainty or poor control persists

Specialist assessment is particularly valuable when symptoms or exacerbations continue despite treatment, the diagnosis remains uncertain, or investigations suggest additional lung disease.

Early referral is warranted for haemoptysis, significant unexplained weight loss, fever, night sweats or other atypical findings. Multimorbidity, particularly cardiovascular disease, may also require coordinated assessment.

For patients being considered for biologics, establish which disease and indication the treatment targets. Selection depends on the applicable asthma or COPD criteria, prior treatment, exacerbation history and relevant biomarkers. GINA strategy report, Chapter 7

What to document at each review

DomainRecord
Diagnostic evidenceAsthma history, exposure history, spirometry and relevant imaging
Current burdenSymptoms, activity limitation, reliever use and exacerbations
Inhaled treatmentICS-containing regimen, dose, device and observed technique
Treatment accessAffordability, availability and adherence barriers
Additional careSmoking cessation, vaccination, rehabilitation and action plan
Follow-upTreatment goals, reassessment date and reasons for referral

Explicit documentation makes the rationale for ICS, bronchodilation and subsequent treatment changes easier to follow across primary and specialist care. GOLD 2027 report, treatment checklists and Chapters 3 and 5